TL;DR — Ipamorelin (a selective ghrelin-receptor agonist) and CJC-1295 (a GHRH analog) are almost always stacked together to raise pulsatile growth hormone and downstream IGF-1 via two different receptors. Real endocrinology literature characterizes their human GH/IGF-1 pharmacodynamics, but no trial has tested long-term anti-aging outcomes, and elevated IGF-1 carries a real, debated theoretical cancer-risk signal from unrelated epidemiological literature.
What Ipamorelin and CJC-1295 are, and why they are stacked together
These are two different drug classes that happen to be used together almost universally in longevity/bodybuilding communities, because they act on two separate, complementary points of the GH-release axis:
- Ipamorelin is a "GHRP" (growth-hormone-releasing peptideA short chain of amino acids — smaller than a full protein — that usually acts on a specific cell-surface receptor rather than a broad metabolic pathway. Full glossary →) — a selective agonist at the ghrelin receptor, which triggers a GH pulse from the pituitary with minimal effect on cortisol or prolactin (a real, published advantage over older GHRPs like GHRP-6, which do raise cortisol/prolactin/appetite more substantially).
- CJC-1295 is a growth-hormone-releasing hormone (GHRH) analog — it acts on the separate GHRH receptor to increase the size and duration of the natural GH pulse the pituitary produces.
Because they hit different receptors, the combination produces a larger GH pulse than either alone — a real, mechanistically sound, and reasonably well-characterized pharmacological effect in human studies.
Primary hallmarks targeted: Deregulated nutrient sensing (GH/IGF-1 axis) · Loss of proteostasis (protein synthesis)
Published human pharmacodynamic studies characterize Ipamorelin's GH-release profile with minimal cortisol/prolactin elevation relative to older GHRPs, and CJC-1295's extended GH-pulse amplitude/duration via GHRH-receptor agonism (endocrinology literature, 2000s–2010s). This is real, replicated human pharmacodynamic data. No trial has tested long-term health or anti-aging outcomes from chronic use of either peptide, alone or combined.
Mechanism — ghrelin-receptor agonism (Ipamorelin) vs. GHRH-analog action (CJC-1295)
| Peptide | Receptor | Reported effect | Hallmark link |
|---|---|---|---|
| Ipamorelin | Ghrelin receptor (GHS-R) | GH pulse, minimal cortisol/prolactin rise | Nutrient sensing |
| CJC-1295 | GHRH receptor | Larger, longer GH pulse amplitude | Nutrient sensing |
| Combined | Both | Additive GH/IGF-1 elevation vs. either alone | Nutrient sensing, proteostasis |
← Swipe for more columns →
The appeal for longevity use is straightforward: GH and IGF-1 decline substantially with age, and restoring more youthful pulsatile GH release is proposed to support lean mass, recovery, and tissue repair. That proposal has real endocrinology behind the mechanism — but "GH/IGF-1 rises measurably" and "this improves healthspanThe portion of life spent in good health, free from chronic disease or disability — distinct from lifespan (total years alive). Full glossary → without meaningful long-term risk" are different claims, and the second one is the one that matters for a longevity decision.
What's actually characterized vs. what's assumed
Characterized: the acute GH/IGF-1 pharmacodynamic response to Ipamorelin + CJC-1295 in humans. Not characterized: the effect of years of elevated IGF-1 from this specific combination on cancer risk, cardiac structure, or insulin sensitivity — the questions that actually determine whether this is a net-positive longevity intervention.
Evidence summary
| Study type | Model | Key reported outcome | Tier |
|---|---|---|---|
| Ipamorelin pharmacodynamics | Human | GH pulse with minimal cortisol/prolactin rise | B |
| CJC-1295 pharmacodynamics | Human | Extended GH pulse amplitude/duration | B |
| Combined long-term outcome trial | Human | None published | — |
| IGF-1/cancer-risk epidemiology | Human, unrelated cohorts | Elevated IGF-1 associated with increased risk in some cancer types | B (separate literature, not this peptide combo directly) |
← Swipe for more columns →
Is the IGF-1/cancer-risk question relevant to you?
Do you have a personal or strong family history of hormone-sensitive cancers (breast, prostate, colorectal)?
The IGF-1-elevation mechanism is directly relevant to your individual risk profile — this is a physician-conversation point, not a peptide-forum one.
The theoretical risk still applies at a population level, but your baseline risk calculus differs — track IGF-1 levels directly rather than assuming safety.
Active or recent history of any malignancy — GH/IGF-1 axis stimulation is a genuine, non-theoretical contraindication here, not a precautionary boilerplate.
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Dosing patterns reported in the community (not a clinical protocol)
Community-reported use typically involves nightly subcutaneous injection (timed to natural nocturnal GH pulses) at doses derived from the pharmacodynamic trials rather than any long-term-outcome trial. TNiC does not provide a specific dosing recommendation — every number in circulation is an extrapolation from acute-response studies, not a validated chronic-use protocol, and doses vary substantially by vendor and source purity.
What long-term GH/IGF-1 elevation actually risks
- IGF-1/cancer-risk association — a real, debated epidemiological signal in unrelated literature linking higher IGF-1 to increased risk in some hormone-sensitive cancers; not proof of causation from this specific peptide combination, but not dismissible either.
- Insulin resistance — chronic GH elevation can worsen insulin sensitivity; relevant if you already have metabolic risk factors.
- Fluid retention / carpal tunnel-like symptoms — reported with GH-axis stimulation broadly.
- Unregulated sourcing — same research-chemical vendor purity/dosing-accuracy risk as other peptides on this list.
Safety, red flags, and contraindications — including the IGF-1/cancer-risk question
- Absolute contraindication: active or recent malignancy, given direct GH/IGF-1 axis stimulation.
- Strong relative caution: personal/family history of hormone-sensitive cancers — discuss with a physician before proceeding.
- Monitor IGF-1 and fasting glucose/HbA1c if using chronically — both are measurable, objective signals this specific mechanism should move.
- No characterized interaction profile exists with other GH-axis-active compounds or medications.
IGF-1
Baseline
Fasting glucose/HbA1c
Baseline
IGF-1
Repeat at 8-12wk
Fasting glucose/HbA1c
Repeat at 8-12wk
Personal tracking template
My GH secretagogue tracking log
| Date | Week | IGF-1 (lab value) | Fasting glucose | Subjective recovery (0–10) | Notes |
|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | Baseline labs before starting |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: IGF-1 rise into a normal-for-age upper range without fasting glucose deterioration. - No effect: No IGF-1 change from baseline. - Stop and reassess: Fasting glucose/HbA1c worsening, new fluid retention, or any new symptom warranting a cancer-risk conversation with a physician.
Track IGF-1 and glucose in the Labs hub
This is one of the few peptide categories where the exact lab values to watch are well-defined — use them.
Open Labs Hub